References
- Croog S. H., Levine S., Testa M. A., Brown B., Bulpitt C. J., Jenkins C. D., Klerman G. L., Williams G. H. The effects of antihypertensive therapy on quality of life. New Eng J Med. 1986; 314: 1657–1664
- Lessem J. N., Rucinka E., Vickers F. F., Espie J., Sromovsky J. A. Long-term Enalapril - a new converting enzyme inhibitor - in the treatment of mild to moderate essential hypertension. Results of a worldwide multiclinic study. Clin Exp Hypertension Theory and Practice 1985; 7(11)1515–1539
- Helgeland A., Strommen R., Hagelund C. H., Tretli S. Enalapril, Atenolol and Hydrochlorothiazide in mild to moderate hypertension. A Comparative Multicentre Study in general practice in Norway. Lancet. 1986; i: 872–875
- The IPPPSH Collaborative Group. Cardiovascular risk and risk factors in a randomised trial of treatment based on the beta-blocker Oxprenolol: The International Prospective Primary Prevention Study in Hypertension (IPPPSH). J Hypertension. 1985; 3: 379–392
- Medical Research Council Working Party. MRC Trial of treatment of mild hypertension: principal results. Br Med J. 1985; 291: 97–104
- Chatellier G., Degoulet P., Devries C., Vu H. A., Plouin P.-F., Ménard J. Symptom prevalence in hypertensive patients. Eur Heart J. 1982; 3(Supp. C)45–52